{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FLT3+Internal+Tandem+Duplication&page=2",
    "query": {
      "condition": "FLT3 Internal Tandem Duplication",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FLT3+Internal+Tandem+Duplication&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T04:16:36.137Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03513484",
      "title": "Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A",
        "Fibroblast Growth Factor Basic Form Measurement",
        "FLT3 Internal Tandem Duplication",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nintedanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2018-11-14",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-21",
      "last_synced_at": "2026-06-11T04:16:36.137Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03513484"
    },
    {
      "nct_id": "NCT02668653",
      "title": "Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Quizartinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 539,
      "start_date": "2016-09-01",
      "completion_date": "2023-06-16",
      "has_results": true,
      "last_update_posted_date": "2024-08-06",
      "last_synced_at": "2026-06-11T04:16:36.137Z",
      "location_count": 11,
      "location_summary": "Gainesville, Florida • Chicago, Illinois • Indianapolis, Indiana + 7 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02668653"
    },
    {
      "nct_id": "NCT01846624",
      "title": "Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML) With Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults",
        "AML (Adult) With 11q23 (MLL) Abnormalities",
        "AML (Adult) With Del (5q)",
        "AML (Adult) With Inv (16) (p13; q22)",
        "AML (Adult) With t (16;16) (p13; q22)",
        "AML (Adult) With t (8; 21) (q22; q22)",
        "Secondary AML (Adult)",
        "Untreated AML (Adult)"
      ],
      "interventions": [
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Midostaurin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David Iberri",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2013-06",
      "completion_date": "2016-08-31",
      "has_results": true,
      "last_update_posted_date": "2018-09-27",
      "last_synced_at": "2026-06-11T04:16:36.137Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01846624"
    },
    {
      "nct_id": "NCT01349049",
      "title": "Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "PLX3397",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2011-11-21",
      "completion_date": "2018-01-09",
      "has_results": true,
      "last_update_posted_date": "2020-03-02",
      "last_synced_at": "2026-06-11T04:16:36.137Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Chicago, Illinois • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01349049"
    },
    {
      "nct_id": "NCT02997202",
      "title": "A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "gilteritinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 356,
      "start_date": "2017-08-16",
      "completion_date": "2023-05-09",
      "has_results": true,
      "last_update_posted_date": "2025-01-17",
      "last_synced_at": "2026-06-11T04:16:36.137Z",
      "location_count": 46,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02997202"
    },
    {
      "nct_id": "NCT01565668",
      "title": "Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia, Myeloid, Acute"
      ],
      "interventions": [
        {
          "name": "AC220",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2012-04",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2019-12-27",
      "last_synced_at": "2026-06-11T04:16:36.137Z",
      "location_count": 18,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01565668"
    },
    {
      "nct_id": "NCT02634827",
      "title": "Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia With FLT3/ITD Mutation",
        "Acute Myeloid Leukemia With Gene Mutations",
        "FLT3 Tyrosine Kinase Domain Point Mutation",
        "Secondary Acute Myeloid Leukemia",
        "Untreated Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Midostaurin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2015-12-30",
      "completion_date": "2018-06-12",
      "has_results": true,
      "last_update_posted_date": "2019-08-07",
      "last_synced_at": "2026-06-11T04:16:36.137Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02634827"
    },
    {
      "nct_id": "NCT03735875",
      "title": "Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia With FLT3/ITD Mutation",
        "Recurrent Acute Myeloid Leukemia",
        "Refractory Acute Leukemia"
      ],
      "interventions": [
        {
          "name": "Quizartinib",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2019-01-25",
      "completion_date": "2023-07-26",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-06-11T04:16:36.137Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03735875"
    },
    {
      "nct_id": "NCT04240002",
      "title": "A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)",
        "Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)"
      ],
      "interventions": [
        {
          "name": "gilteritinib",
          "type": "DRUG"
        },
        {
          "name": "fludarabine",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "granulocyte colony-stimulating factor (G-CSF)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "6 Months to 21 Years"
      },
      "enrollment_count": 9,
      "start_date": "2020-09-04",
      "completion_date": "2025-03-17",
      "has_results": true,
      "last_update_posted_date": "2026-01-05",
      "last_synced_at": "2026-06-11T04:16:36.137Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04240002"
    },
    {
      "nct_id": "NCT02624570",
      "title": "Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Acute Myeloid Leukemia (AML) With",
        "FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)"
      ],
      "interventions": [
        {
          "name": "Midostaurin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2020-07-15",
      "last_synced_at": "2026-06-11T04:16:36.137Z",
      "location_count": 44,
      "location_summary": "Phoenix, Arizona • Berkeley, California • Duarte, California + 35 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02624570"
    }
  ]
}